Management of metastatic spinal cord compression

Area of Science:

• Oncology
• Neurology
• Radiotherapy

Background:

• Metastatic spinal cord compression (MSCC) affects 3-7% of cancer patients, presenting an oncologic emergency.
• Early diagnosis and prompt treatment are crucial to prevent severe neurological deficits like paralysis and incontinence.
• Ambulatory patients at diagnosis generally have better treatment response and longer survival rates.

Purpose of the Study:

• To outline the diagnostic and therapeutic strategies for metastatic spinal cord compression.
• To emphasize the importance of timely intervention for optimal patient outcomes.
• To provide guidance on the role of imaging, radiotherapy, and surgery in managing MSCC.

Main Methods:

• Magnetic resonance imaging (MRI) is the gold standard for diagnosing MSCC, identifying compression in patients with back pain and normal neurological exams.
• Radiotherapy is the primary treatment modality for most MSCC cases.
• Surgical intervention is reserved for specific indications, such as spinal instability or diagnostic uncertainty, with a preference for aggressive resection and stabilization over laminectomy.

Main Results:

• MRI effectively diagnoses MSCC and helps delineate lesion extent, aiding radiation oncologists in treatment planning.
• Radiotherapy, even hypofractionated regimens, is effective and can be administered 7-10 days post-surgery without increasing myelopathy risk.
• Moderate-dose dexamethasone is recommended in early treatment phases.

Conclusions:

• Metastatic spinal cord compression necessitates urgent, multidisciplinary management involving imaging, radiotherapy, and selective surgery.
• Post-treatment surveillance is vital, with MRI reserved for suspected recurrence or complications.
• Advances in radiotherapy, including hypofractionation, offer effective treatment options with acceptable safety profiles.